News

MindRhythm Expands Beyond Strokes to Include Concussions

MindRhythm, a medical device technology company focused on preventing neurological injury, announces today the expansion of its exclusive worldwide stroke licensing agreement with the University of California San Francisco (UCSF) to include concussions.

FDA Grants Orphan Drug Designation for Vanda's Cholera Treatment

Vanda Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VPO-227, a drug discovered by UCSF researcher Alan Verkman, PhD, for the treatment of cholera. more

Erasca Collaborates with Pfizer

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced a clinical trial collaboration and supply agreement (CTCSA) with Pfizer Inc. for the CDK4/6 inhibitor...

Nested Therapeutics Launches With $125 Million Financing

Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers that are founded on UCSF professor Kevan Shokat's technology, today announced the completion of a $90 million Series A financing led by the Life Sciences Investing...

Exai Bio Novel RNA-based Liquid Biopsy Platform May Detect Colorectal Cancer Early

Exai Bio, a next-generation liquid biopsy company, and researchers led by Professor Hani Goodarzi at UCSF are presenting data from a new study in a poster entitled "Serum-based colorectal cancer detection using orphan noncoding RNAs" at the 2022 European Society of Medical Oncology (ESMO) meeting.

Erasca Presents Promising Preliminary Phase 1 Monotherapy Data

Erasca, Inc., a clinical-stage precision oncology company founded by University of California chemical biologist Kevan Shokat, today announced promising preliminary Phase 1/1b monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in BRAF-driven and RAS/MAPK-altered solid tumors...

Arsenal Biosciences Closes $220 Million Series B Financing

Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors founded on Medtech developed by Kole Roybal and Alex Marson at the University of California, San Francisco, today announced the close of a $220 million...

Talking Tech Transfer With Anthony Francis

With a career that already stretches decades, Francis has a lot of wisdom to share, such as the need to understand that universities and investors trade in different currencies: innovation and money. MORE

Trial Library Emerges Out of Stealth with $5 Million in Seed Funding

Fresh Capital Used to Build on Trial Library's Mission to Improve Health Equity by Expanding Access to Cancer Precision Medicine Spearheaded by Dr. Hala Borno, Leading UCSF oncologist and Health Equity Researcher. Press Release

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion

The proposed acquisition brings leading sickle cell disease expertise to Pfizer with potential combined worldwide peak sales of more than $3 billion to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics...